Click here to close now.




















Welcome!

News Feed Item

Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2015

SINGAPORE, Aug. 6, 2014 /PRNewswire/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, today announced financial results for its first fiscal quarter ended 30 June 2014 ("Q1 FY15").

Quarter Highlights and Recent Developments:

  • Total revenue was US$80.2 million, representing a 5% growth from the quarter ended 30 June 2013 ("Q1 FY14"). Product revenue increased 8% year-over-year, partially offset by lower licensing and royalty revenue.
  • Cardiac Diagnostic division sales grew substantially from Q1 FY14. This is a significant achievement as it represents a new product category and demonstrates the Company's ability to pursue growth through portfolio expansion.
  • In the drug-eluting stent (DES) business, both the BioMatrix™ family of stents and Excel recorded double-digit volume increases compared with Q1 FY14.
  • Although the Company's DES average selling prices (ASPs) were lower in comparison with Q1 FY14 which is in line with the trend observed across the industry, the Company's ASPs were relatively steady as compared with the fourth quarter of FY14 ("Q4 FY14").
  • Under the leadership of Mr. Yoh-Chie Lu, Biosensors' Chairman and interim CEO, the Company continued to make steady progress in improving its operational efficiency through cost reduction and other initiatives, as observed in the gradual reduction in sales and marketing ("S&M") expense as a percentage of product revenue versus Q1 FY14.

"In the first quarter, although weak market sentiments continued to pressure our DES revenue, we are encouraged by the good volume growth compared to Q1 FY14," said Mr. Lu. "In addition, our Cardiac Diagnostic segment recorded satisfactory growth and improved profit which is in line with our product diversification strategy. We remain excited about this segment's potential. As a result of our cost reduction initiatives, we also reduced our sales and marketing expenses as a percentage of our product revenue compared to a year ago."

Performance Summary for Q1 FY15

For Q1 FY15, Biosensors reported total revenue of US$80.2 million, representing a 5% increase from US$76.7 million in Q1 FY14, as a result of higher product revenue partially offset by lower licensing and royalty revenue. Product revenue of US$70.5 million represents an 8% year-on-year increase from Q1 FY14, largely attributable to growth in Cardiac Diagnostics revenue, which rose to US$4.4 million from US$0.7 million in the same quarter last year. The Company's Critical Care Product ("CCP") business segment also achieved a record quarter of US$4.4 million, representing a 28% growth from the same quarter last year.

Licensing and royalty revenue for Q1 FY15 was US$9.7 million, representing a 16% decrease from US$11.6 million in the same quarter last year.

Gross margin on total product sales was 71% for the quarter compared with 75% for Q1 FY14. This change in gross margin reflects the change in the Company's product mix as well as DES price erosion in various geographic regions as compared to Q1 FY14.

Total operating expense as a percentage of product revenue for the quarter was 64%, which is comparable to the same quarter last year. 

In detail, the quarter's sales and marketing ("S&M") expense was US$26.9 million; general and administrative ("G&A") expense was US$10.7 million; and research and development ("R&D") expense was US$7.0 million.

Net profit for Q1 FY15 was US$9.9 million, or 0.58 US cents basic and diluted earnings per share ("basic EPS" and "diluted EPS" respectively). This compares to a net profit of US$12.1 million, or basic EPS of 0.70 US cents and diluted EPS of 0.69 US cents, for Q1 FY14.

Financial Guidance for FY15

For the fiscal year ending 31 March 2015 ("FY15"), the management expects challenging market conditions such as increased competition and price erosion to continue in the global DES market. The Company will continue to bring new innovative products to the market, expand its existing product portfolio, and enter new geographical territories to improve its overall performance.

"Biosensors is transitioning from being heavily reliant on licensing and royalty income to becoming more capable of generating profits from its own operations, which is ultimately more sustainable," said Mr. Lu. "The Company is also taking steps to improve the operational efficiency and productivity for our existing businesses and markets. We are happy to see the progress we have achieved so far, especially in the area of sales and marketing expense. At the same time, we will continue to actively identify new growth opportunities, including acquiring new businesses and other ways to improve our overall performance.  We firmly believe that we have the right combination of leadership, strategy and resources to propel us forward and enable us to become a leading international medical device player."

Media/Investor Relations Contact

Wong Teck Yenn
Director, Investor Relations
Tel: (65) 6213 5777
Email: [email protected]

About Biosensors International Group, Ltd

Biosensors International Group, Ltd. develops, manufactures and markets innovative medical devices, aiming to improve patients' lives through pioneering medical technology that pushes forward the boundaries of innovation. Founded in 1990, the Company was listed on the Mainboard of the Singapore Stock Exchange in 2005.

The Group currently operates through four business units ("BU"): the Cardiovascular BU, composed primarily of Excel™ and the BioMatrix™ family of drug-eluting stents and stent technologies such as BA9™; the Cardiac Diagnostic BU, including Spectrum Dynamics products that offer advanced medical imaging and clinical solutions to help interventional cardiologists determine the most appropriate treatment for patients; the Peripheral Intervention BU, offering solutions for the treatment of patients with peripheral arterial disease; and the Critical Care Products BU, which fosters the development of critical care catheters, hemodynamic monitoring, and related devices used during heart surgery procedures, vascular surgery procedures and intensive care treatment.

The Group has operations worldwide and is headquartered in Singapore.

For more information, please visit www.biosensors.com.

Forward-Looking Statements

Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe," "project" or "continue" or the negative thereof or other similar words. All forward looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.

SOURCE Biosensors International Group, Ltd.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Any Ops team trying to support a company in today’s cloud-connected world knows that a new way of thinking is required – one just as dramatic than the shift from Ops to DevOps. The diversity of modern operations requires teams to focus their impact on breadth vs. depth. In his session at DevOps Summit, Adam Serediuk, Director of Operations at xMatters, Inc., will discuss the strategic requirements of evolving from Ops to DevOps, and why modern Operations has begun leveraging the “NoOps” approa...
IBM’s Blue Box Cloud, powered by OpenStack, is now available in any of IBM’s globally integrated cloud data centers running SoftLayer infrastructure. Less than 90 days after its acquisition of Blue Box, IBM has integrated its Blue Box Cloud Dedicated private-cloud-as-a-service into its broader portfolio of OpenStack® based solutions. The announcement, made today at the OpenStack Silicon Valley event, further highlights IBM’s continued support to deliver OpenStack solutions across all cloud depl...
In their Live Hack” presentation at 17th Cloud Expo, Stephen Coty and Paul Fletcher, Chief Security Evangelists at Alert Logic, will provide the audience with a chance to see a live demonstration of the common tools cyber attackers use to attack cloud and traditional IT systems. This “Live Hack” uses open source attack tools that are free and available for download by anybody. Attendees will learn where to find and how to operate these tools for the purpose of testing their own IT infrastructu...
Red Hat is investing in Tesora, the number one contributor to OpenStack Trove Database as a Service (DBaaS) also ranked among the top 20 companies contributing to OpenStack overall. Tesora, the company bringing OpenStack Trove Database as a Service (DBaaS) to the enterprise, has announced that Red Hat and others have invested in the company as a part of Tesora's latest funding round. The funding agreement expands on the ongoing collaboration between Tesora and Red Hat, which dates back to Febr...
SYS-CON Events announced today that DataClear Inc. will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. The DataClear ‘BlackBox’ is the only solution that moves your PC, browsing and data out of the United States and away from prying (and spying) eyes. Its solution automatically builds you a clean, on-demand, virus free, new virtual cloud based PC outside of the United States, and wipes it clean...
WSM International, the pioneer and leader in server migration services, has announced an agreement with WHOA.com, a leader in providing secure public, private and hybrid cloud computing services. Under terms of the agreement, WSM will provide migration services to WHOA.com customers to relocate some or all of their applications, digital assets, and other computing workloads to WHOA.com enterprise-class, secure cloud infrastructure. The migration services include detailed evaluation and planning...
Cloud and datacenter migration innovator AppZero has joined the Microsoft Enterprise Cloud Alliance Program. AppZero is a fast, flexible way to move Windows Server applications from any source machine – physical or virtual – to any destination server, in any cloud or datacenter, using its patented container technology. AppZero’s container is also called a Virtual Application Appliance (VAA). To facilitate Microsoft Azure onboarding, AppZero has two purpose-built offerings: AppZero SP for Azure,...
SYS-CON Events announced today that G2G3 will exhibit at SYS-CON's @DevOpsSummit Silicon Valley, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Based on a collective appreciation for user experience, design, and technology, G2G3 is uniquely qualified and motivated to redefine how organizations and people engage in an increasingly digital world.
SYS-CON Events announced today that IceWarp will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. IceWarp, the leader of cloud and on-premise messaging, delivers secured email, chat, documents, conferencing and collaboration to today's mobile workforce, all in one unified interface
In 2014, the market witnessed a massive migration to the cloud as enterprises finally overcame their fears of the cloud’s viability, security, etc. Over the past 18 months, AWS, Google and Microsoft have waged an ongoing battle through a wave of price cuts and new features. For IT executives, sorting through all the noise to make the best cloud investment decisions has become daunting. Enterprises can and are moving away from a "one size fits all" cloud approach. The new competitive field has ...
In his session at @ThingsExpo, Lee Williams, a producer of the first smartphones and tablets, will talk about how he is now applying his experience in mobile technology to the design and development of the next generation of Environmental and Sustainability Services at ETwater. He will explain how M2M controllers work through wirelessly connected remote controls; and specifically delve into a retrofit option that reverse-engineers control codes of existing conventional controller systems so the...
Everyone talks about continuous integration and continuous delivery but those are just two ends of the pipeline. In the middle of DevOps is continuous testing (CT), and many organizations are struggling to implement continuous testing effectively. After all, without continuous testing there is no delivery. And Lab-As-A-Service (LaaS) enhances the CT with dynamic on-demand self-serve test topologies. CT together with LAAS make a powerful combination that perfectly serves complex software developm...
The Internet of Things is in the early stages of mainstream deployment but it promises to unlock value and rapidly transform how organizations manage, operationalize, and monetize their assets. IoT is a complex structure of hardware, sensors, applications, analytics and devices that need to be able to communicate geographically and across all functions. Once the data is collected from numerous endpoints, the challenge then becomes converting it into actionable insight.
With the proliferation of connected devices underpinning new Internet of Things systems, Brandon Schulz, Director of Luxoft IoT – Retail, will be looking at the transformation of the retail customer experience in brick and mortar stores in his session at @ThingsExpo. Questions he will address include: Will beacons drop to the wayside like QR codes, or be a proximity-based profit driver? How will the customer experience change in stores of all types when everything can be instrumented and a...
Enterprises can achieve rigorous IT security as well as improved DevOps practices and Cloud economics by taking a new, cloud-native approach to application delivery. Because the attack surface for cloud applications is dramatically different than for highly controlled data centers, a disciplined and multi-layered approach that spans all of your processes, staff, vendors and technologies is required. This may sound expensive and time consuming to achieve as you plan how to move selected applicati...